Osteoarthritis is a highly prevalent medical condition among Canadians that causes progressive degradation of cartilage in joints like knees, hips and spine. As the population ages, cases of osteoarthritis are on the rise in Canada. While joint replacement surgery has remained the gold standard treatment for end-stage osteoarthritis, it is an invasive option and not always suitable for mild-to-moderate cases. Viscosupplementation, a non-surgical treatment involving injections of hyaluronic acid into the knee joint, has gained acceptance as an alternative to medication and a possible delay tactic for joint replacement.
How Does Canada Viscosupplementation Work?
Hyaluronic acid is a naturally occurring lubricating fluid found in healthy cartilage. In osteoarthritic joints, the levels of hyaluronic acid deplete over time as the cartilage degrades. Viscosupplementation therapy involves injecting a gel-like formulation of hyaluronic acid derivative deep into the knee joint space. The injections help supplement the body's depleted levels of hyaluronic acid and restore the shock absorbing and lubricating qualities of synovial fluid. This lubricates and cushions the joint, easing pain and improved mobility by reducing bone-on-bone contact. A typical treatment regimen involves 3-5 weekly injections.
Rising Treatment Uptake
According to statistics from Canada's health insurance boards, claims for viscosupplementation injections have significantly risen in recent years. It is now one of the widely used non-surgical treatment methods for knee osteoarthritis. The increased awareness and acceptance is mainly attributed to its proven efficacy and safety profile supported by clinical studies. Unlike older-generation HA products, modern formulations incorporate advanced manufacturing and cross-linking technology to last longer in the joint with durable pain relief. They have shown to successfully reduce pain and disability on par with steroid injections.
Cost Savings For Public Healthcare
Viscosupplementation offers major cost savings potential for Canada's public healthcare system compared to more expensive options like total knee replacement surgeries that can cost upwards of $25,000 per case. Knee osteoarthritis is a leading cause of medical costs and lost productivity. Recent economic analyses reveal that just one viscosupplementation injection regimen can potentially delay the need for joint replacement by 18 months on average, thereby curbing downstream surgical expenses. This makes it an attractive proposition for insurance providers trying to curb pharmaceutical costs and reduce dependency on surgeries.
Product Innovations And Competition
Anticipating further growth, leading pharmaceutical companies are investing heavily in newer viscosupplement formulation research. Major players like Sanofi, Ferring Pharmaceuticals and Bioventus regularly launch advanced products in Canada with proprietary cross-linking and formulation technologies that provide longer relief. Competition is also strong from smaller domestic players and generic HA brands that offer more affordable options. This competition has lowered viscosupplementation treatment costs notably over the past decade while maintaining quality and safety. Today, a standard 3-5 injection regimen can easily cost under $1000.
Physician Acceptance And Guidelines
Credible clinical evidence and proven outcomes have led to viscosupplementation gaining formal acceptance in standard treatment guidelines set by Canadian orthopedic societies. The majority of practicing physicians now consider it a first-line treatment alternative to medications for mild-moderate knee osteoarthritis. It enables them to delay or even avoid referring patients for joint replacement in some cases, easing pressures on an already burdened surgical system. Most private and public health insurance plans in Canada also provide full or partial reimbursement for viscosupplementation therapy. This widespread coverage and acceptance at institutional levels have been pivotal in driving the overall growth.
Future Potential For Expanding Uses
With the expanding aging demographic expected to strain healthcare budgets, viscosupplementation looks set to play an even bigger role in Canada's osteoarthritis management framework. Researchers are optimistic about its future potential for new applications beyond knees. Several ongoingstudies are evaluating efficacy for hard to treat small joints like ankles, as well as efficacy combined with other intra-articular medicines. Innovation is also bringing sustained-release formulations promising pain relief for 6 months or longer from just one-time injections. If successful, such products could further increase viscosupplementation uptake multifold and achieve even greater cost savings for Canadian healthcare.
Viscosupplementation has emerged as mainstream treatment approach for knee osteoarthritis in Canada backed by strong evidence and cost advantages over alternatives. Supported by health authorities, insurers as well as physician adoption, it will likely continue playing a vital non-surgical role in tackling the escalating social and economic burden from this debilitating condition. Future formulation advances also promise expansion to other joints and even longer acting options.
Get more insights on this topic: https://www.newsanalyticspro.com/canada-viscosupplementation-a-non-surgical-treatment-option-for-knee-osteoarthritis-in-canada/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.(https://www.linkedin.com/in/ravina-pandya-1a3984191)
